HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sun Sets On California Firm: FTC Pandemic Fraud Complaint Follows Criminal Indictment

Executive Summary

Golden Sunrise business owner Huu Tieu marketed a package of herbal mixtures branded “Emergency D-Virus Plan of Care” with claims to treat COVID-19, says FTC complaint. Tieu was indicted on criminal charges two weeks before FTC filed complaint.

You may also be interested in...



No Hiding Bogus Coronavirus Claims From US Regulators In Social Media Or With Vague Terms

“I don’t know if there’s a misconception that a different set of adverting rules apply to social media," says FTC attorney Christine DeLorme during FDLI conference. The FTC also sees "a lot of attempts at disclaimers. They might say, ‘Of course there’s no cure for COVID, but...’"

COVID-19 False Advertising Symptoms In US Exceed FTC’s Prognosis For Number, Variety

FTC Division of Advertising Practices anticipated surge of false ads for consumer health products related to COVID-19 but it didn’t expect quite the number as well as the variety of bogus claims it’s found, says Assistant Director Richard Cleland.

Consumer Health Fraud Didn’t Start With COVID-19, Senators And Witnesses Say At Hearing

“Dietary supplements are among the most poorly regulated consumer products,” CSPI policy director tells Senate Manufacturing, Trade and Consumer Protection Subcommittee. Ranking member Blumenthal says scams won’t end soon. “We’re six months into this pandemic with no end in sight.”

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150312

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel